Search this site powered by FreeFind




Breast Cancer Statistics - How Breast Cancer Survival Rates Increased 50%


Breast cancer statistics show that over 1.2 million persons will be diagnosed with breast cancer worldwide this year, according to the World Health Organization. For breast cancer and prevention, it has long been known that regular physical activity has been shown to decrease the likelihood of having breast cancer. What has not been known or studied has been the effect of regular physical activity on the breast cancer survival rates or likelihood of death in women that already have breast cancer. That is, until now.

The breast cancer statistics and findings as reported by the American Medical Association's Journal of the American Medical Association (JAMA) in May 2005 were astounding! Certain participants in the study of women with Stage I, II or III breast cancer achieved a 50% reduction in the death rate from breast cancer.

Here are these breast cancer statistics: the journal reported that in the study 2,987 female registered nurses had been diagnosed with breast cancer during the years 1984-1998. What the study found was that the women who had physical activity equivalent to walking at a steady pace of 2.0-2.9 miles per hour for 3-5 hours a week had a death rate of only 50% of the death rate of women who had physical activity equivalent to walking less than one hour a week. The conclusion of the breast cancer statistics in the study was that physical activity after breast cancer has been diagnosed may reduce the risk of death from breast cancer. The study found that there was little evidence of any relation between increased physical activity and increased benefit.

It's time to dust off those walking shoes!

As a physical activity, walking can be done almost anytime by anyone anywhere. All that's needed is a good pair of walking shoes. Walking is fun and reduces stress. As for injuries, walking has the lowest injury rate of all the various kinds of exercise.

You can walk with a partner, friend, family member or dog, maybe even a neighbor's dog. Or you can walk with your favorite headset and music. If you are walking outdoors with a headset, keep one ear open to hear the sounds around you.

As for basic walking tips:

· As you begin regular walking, take it easy. Standard advice is to check with your physician before starting any exercise program. If it's been years or decades since you walked regularly, perhaps you can begin with 5 minutes of walking and slowly increase your time and distance.

· Walking at a pace of 75-95 steps a minute will have you walking at a speed of about 2-3 miles per hour.

· Walk with your head up, looking out in front of you. Do not walk looking down right in front of you except to navigate any obstacles.

· Really take it easy the first 5 minutes of walking to warm up. Afterwards, gently stretch for 5-10 minutes while your muscles are warm.

· Practice good walking form. Your arms should swing naturally in the direction you're walking, not from side to side across your body. Your foot should strike the ground on your heel, then a rolling motion forward toward the ball of your foot, then pushing off with your toes.

And here are some basic walking shoes tips:

· Buy your walking shoes from a sporting shoes store with large selections. That will give you plenty of choices. And buy your walking shoes later in the day when your feet will be larger.

· Buy cushioned, supportive walking shoes. To see if a shoe is supportive, do this test -- take a shoe and turn it upside down. Holding each end of the shoe, try to fold it. If you find the shoe bends in the middle, then that shoe is not a supportive shoe. A supportive shoe should bend where your foot normally bends, near your toes.

· You should allow the width of your index finger between the end of your shoe and the end of your longest toe, or about one-half inch.

· Buy two pairs of walking shoes, one for home and one for the car or workplace. And if one pair gets wet, you can use the other pair that day.

Walking is the closest thing to the perfect exercise. In today's fast-paced society, regular walking can be a welcomed break from the stress of the day. Maybe you'll get to know your neighborhood or neighbors better. There may be walking trails you've never seen but wanted to.

Wherever and however you choose to walk, not only can the experience be fun, you'll know you're being good to your body in a variety of ways. Besides the incredible breast cancer statistics and findings of the breast cancer study, walking helps with weight control and bone strength, elevates mood, helps build and maintain healthy muscles, joints and heart. With so many great health benefits, why not get started walking today!

Copyright 2005 InfoSearch Publishing

Olinda Rola is President of InfoSearch Publishing and webmaster of http://www.safemenopausesolutions.com - a website of natural solutions for a variety of health problems. For information about preventing breast cancer, visit Breast Cancer and Prevention to read more.


MORE RESOURCES:
Breastfeeding for at least six months might lower the risk of developing so-called "triple negative" breast cancer, an aggressive form of the disease that is more common in black and younger women, according to a study published on Monday in the journal Cancer, the Seattle Post-Intelligencer reports (Paulson, Seattle Post-Intelligencer, 8/24).

A new promising enzyme target for a specific type of breast cancer, Brk, has been identified in research published on August 21, 2008 in the Proceedings of the National Academy of Sciences (PNAS.) In a specific subset of breast cancer patients, the tumor cells produce high levels of the protein ErbB2 (also called HER2) which pushes the cells to proliferate without limit, a characteristic common of all cancers.

The American Medical Student Association (AMSA), the nation's oldest and largest, independent association for physicians-in-training, announces the commencement of AMSA Academy, a training ground for physician leaders. Established by students, for students, AMSA Academy takes medical students through the core competencies of leadership and project implementation, while building on key principles of important topics in medicine. There are currently 22 programs offered.

Happiness and optimism may play a role against breast cancer while adverse life events can increase the risk of developing the disease, according to a study by Professor Ronit Peled, at Ben-Gurion University of the Negev in Israel. An article on the study titled "Breast Cancer, Psychological Distress and Life Events among Young Women," was just published in the British journal BMC Cancer (8:245, August 2008).

Feelings of happiness and optimism play a positive role against breast cancer. Research published in the open access journal BMC Cancer suggests that while staying positive has a protective role, adverse life events such as the loss of a parent or close relative, divorce or the loss of a spouse can increase a woman's risk of developing the disease.

New research may explain why breast cancer tends to be more aggressive in women with denser breast tissue. Breast cancer cells grown in dense, rigid surroundings step up their invasive activities, Vanderbilt-Ingram Cancer Center investigators report in the Sept. 9 issue of Current Biology. The findings suggest a cellular mechanism for the correlation between human breast tissue density and tumor aggressiveness.

Two independent research groups have found that simultaneous inhibition of two signaling pathways resulted in substantially enhanced antitumor effects in mouse models of prostate and breast cancer. In an accompany commentary, Steven Grant, at Virginia Commonwealth University Health Science Center, Richmond, discusses the clinical importance of these studies and highlights some of the questions that still need to be answered.

A new study published on bmj.com argues that for older women, health related quality of life can be improved by hormone replacement therapy (HRT). The authors recommend that HRT guidelines should be revised with this most current evidence taken into consideration. Earlier studies have shown that HRT has the potential for general improvements in quality of life measures - how patients feel or function.

Duke University chemists have patented an efficient technique for synthesizing a marine algae extract in sufficient quantities to now test its ability to inhibit the growth of cancerous cells while leaving normal cells unaffected. The researchers also deduced that this molecule -- called largazole -- acts on cells through the same chemical mechanism as other anti-cancer compounds on the market or in clinical trials.

Seeking to improve on nature, scientists used a spice-based compound as a starting point and developed synthetic molecules that, in lab settings, are able to kill cancer cells and stop the cells from spreading. The researchers are combining organic chemistry, computer-aided design and molecular biology techniques in developing and testing pharmaceutical compounds that can fight breast and prostate cancer cells.

ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that the first patient has been treated in a global Phase 3 clinical trial of IMC-1121B, its anti-vascular endothelial growth factor receptor-2 (VEGFR-2) IgG1 monoclonal antibody, in women with metastatic breast cancer.

Advocates, including those for breast cancer patients, are concerned about their relationship with pharmaceutical company Genentech following Roche's bid for the company, the

A decade-long Nebraska study that showed disparities in breast and cervical cancer screenings could have spurred changes that raised the percentage of women screened in the state. "Disparities in screening between racial and ethnic groups, even in a homogeneous state such as Nebraska, are a problem and by digging into some of the differences we were able to have an impact on breast and cervical cancer screening," said lead study author Shingairai Feresu, Ph.D.

Women who survive breast cancer for at least five years after treatment have an 89% chance that they will not have a recurrence of the cancer after 10 years and an 81% chance after 15 years, according to a study published online Tuesday in the Journal of the National Cancer Institute,

Research by scientists at the University of Sheffield suggests that the combination of zoledronic acid (a drug used to prevent bone loss) and chemotherapy agent doxorubicin could stop the growth of breast cancer tumours. Dr Alexis Willett, Policy Manager at Breakthrough Breast Cancer, says: "Breakthrough welcomes any research which investigates new uses for existing treatments to help benefit people with breast cancer.

An article published in The Lancet Oncology reports that postmenopausal women with breast cancer who are on endocrine treatment are likely to experience arthralgia and arthritis (joint symptoms) if they previously have used hormone replacement therapy (HRT), received a hormone-receptor positive tumor diagnosis, undergone chemotherapy, received treatment with anastrozole versus tamoxifen, or been obese.

Scientists in the UK and Finland have discovered that a new combination of the chemotherapy drug doxorubicin and the bone-protecting drug zoledronic acid, both of which are considerably cheaper than herceptin, stopped breast cancer tumors growing in mice. Experts suggest that since both drugs are already in use, and if the combination proves effective and safe in human clinical trials, it should not take as long for it to be available as a new treatment for patients.

Breast cancer patients and their physicians may make more informed, long-term treatment decisions using risk assessment strategies to help determine probability of recurrence, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reported in the Aug. 12 online issue of the Journal of the National Cancer Institute.

Breast cancer patients and their physicians may make more informed, long-term treatment decisions using risk assessment strategies to help determine probability of recurrence, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reported in the Aug. 12 online issue of the Journal of the National Cancer Institute.

Famous names from the fashion, television, radio and music industries have come together to back Fashion Targets Breast Cancer® (FTBC) UK in an advertising campaign which subtly plays on the topic of celebrity charity endorsement. Natalie Imbruglia, Anna Friel, Alan Carr, Edith Bowman and Twiggy have been shot by acclaimed photographer Rankin wearing their FTBC T-shirts with pride for the campaign from leading charity Breakthrough Breast Cancer which aims to raise £1m.

US researchers estimated that the risk of relapse for breast cancer patients who were cancer-free for five years after systemic therapy (chemotherapy, hormone therapy, or both, as well as surgery) was not negligible although it was probably lower than many people realized.

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer.

American Airlines, the world's largest airline, and Susan G. Komen for the Cure®, the world's largest breast cancer organization, announced an expanded partnership with the unveiling of two specially co-branded aircraft, an American Airlines Boeing 757 and an American Eagle Embraer 145, each incorporating the renowned vivid pink-ribbon motif.

Geron Corporation (Nasdaq: GERN) announced the enrollment of the first patient in a clinical trial of its telomerase inhibitor drug, GRN163L, in locally recurrent or metastatic breast cancer. The primary objective of the Phase I/II, dose escalation study is to determine the safety, maximum tolerated dose (MTD) and objective response rate of GRN163L when administered intravenously in combination with a paclitaxel/bevacizumab regimen in this patient population.

A new discovery may lead to more effective screening and treatment for patients with a difficult to recognize syndrome characterized by tumor-like growths and a high risk of developing specific cancers. The research, published by Cell Press in the August 7 issue of the American Journal of Human Genetics, is the first in over thirteen years to identify an alternate susceptibility gene for Cowden syndrome (CS) and related disorders.

home | site map| privacy policy
© 2008, Celerity Consultants, Mumbai, India, All Rights Reserved